July 28, 2023HemaSphereOpen Access

Early mantle cell lymphoma progression is linked to a ~24-month shorter median overall survival.

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Mantle Cell Lymphoma (n=1367). Intervention: Early progression (POD24) after first-line treatment vs. Late progression (relapse ≥24 months). Primary outcome: Median overall survival (months).

Q: What does this research mean for the field?

Patients with mantle cell lymphoma who experience early progression within 24 months of first-line treatment have a significantly inferior median overall survival of 13 months compared to 37 months for those with later relapse. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Why the study?

Mantle cell lymphoma is currently considered incurable, and while some patients achieve prolonged remission after first-line chemoimmunotherapy, many require multiple treatment lines.

What are the real-world treatment trajectories, progression-free survival, and overall survival outcomes across multiple lines of therapy in patients with mantle cell lymphoma?

Population

1367 patients diagnosed with MCL between 2006-2018 in the Swedish Lymphoma Register

Comparison

Treatment strategies and lines of therapy across patient trajectories

Design

Nationwide population-based registry cohort study

Follow-up

Median 6.8 years

Key result

Patients with mantle cell lymphoma who experienced early progression within 24 months of first-line treatment had an inferior median overall survival of 13 months compared to 37 months for those with later relapse.

Authors

MJMats Jerkeman SESara Ekberg IGIngrid Glimelius

Discussion

Member takes

Overview

Early progression within 24 months after first-line MCL therapy identifies high-risk patients; leaves open optimal sequencing of subsequent therapies.

Study Design

Type

Observational (n=1,367)

Multicenter

Yes

Structured PICO

What are the real-world treatment trajectories, progression-free survival, and overall survival outcomes across multiple lines of therapy in patients with mantle cell lymphoma?

Population

1,367 patients diagnosed with mantle cell lymphoma in Sweden between 2006 and 2018, with a median age of 71 years, were followed for a median of 6.8 years to assess treatment trajectories and survival.

Exposure

Various treatment strategies including watch-and-wait, rituximab-bendamustine (BR), and Nordic MCL2 across multiple lines of therapy

Outcome

Overall survival (OS) and progression-free survival (PFS)hard clinical

Main Result

Absolute Event Rate: 13% vs 37%

This nationwide Swedish cohort provides real-world benchmarks for progression-free survival across multiple lines of therapy in mantle cell lymphoma, demonstrating progressively shorter remissions with subsequent treatments.

Limitations

No central review of pathology was performed.
Pathology reports often lacked information on histological subtype and Ki-67 expression.
TP53 mutation analysis was not part of standard diagnostic work-up during the study period.
Ibrutinib and other BTK-inhibitors were not reimbursed in Sweden during the study period.

Cite This Study

Jerkeman et al. (2023) conducted an observational in Mantle Cell Lymphoma (n=1,367). Early progression (POD24) after first-line treatment vs. Late progression (relapse ≥24 months) was evaluated on Median overall survival (months). Patients with mantle cell lymphoma who experienced early progression within 24 months of first-line treatment had an inferior median overall survival of 13 months compared to 37 months for those with later relapse.

synapsesocial.com/papers/6aa9427ea9624f76b4cdd00d https://doi.org/10.1097/hs9.0000000000000928

View Full Paper

Ask AI

Bookmark

July 28, 2023HemaSphereOpen Access

Early mantle cell lymphoma progression is linked to a ~24-month shorter median overall survival.

View Full Paper

Ask AI

Bookmark

Why the study?

Mantle cell lymphoma is currently considered incurable, and while some patients achieve prolonged remission after first-line chemoimmunotherapy, many require multiple treatment lines.

What are the real-world treatment trajectories, progression-free survival, and overall survival outcomes across multiple lines of therapy in patients with mantle cell lymphoma?

Population

1367 patients diagnosed with MCL between 2006-2018 in the Swedish Lymphoma Register

Comparison

Treatment strategies and lines of therapy across patient trajectories

Design

Nationwide population-based registry cohort study

Follow-up

Median 6.8 years

Key result

Authors

MJMats Jerkeman SESara Ekberg IGIngrid Glimelius

Discussion

Member takes

Overview

Early progression within 24 months after first-line MCL therapy identifies high-risk patients; leaves open optimal sequencing of subsequent therapies.

Study Design

Type

Observational (n=1,367)

Multicenter

Yes

Structured PICO

What are the real-world treatment trajectories, progression-free survival, and overall survival outcomes across multiple lines of therapy in patients with mantle cell lymphoma?

Population

Exposure

Various treatment strategies including watch-and-wait, rituximab-bendamustine (BR), and Nordic MCL2 across multiple lines of therapy

Outcome

Overall survival (OS) and progression-free survival (PFS)hard clinical

Main Result

Absolute Event Rate: 13% vs 37%

Limitations

No central review of pathology was performed.
Pathology reports often lacked information on histological subtype and Ki-67 expression.
TP53 mutation analysis was not part of standard diagnostic work-up during the study period.
Ibrutinib and other BTK-inhibitors were not reimbursed in Sweden during the study period.

Cite This Study

synapsesocial.com/papers/6aa9427ea9624f76b4cdd00d https://doi.org/10.1097/hs9.0000000000000928

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark